NCT02779764已完成3 期
A Phase 3, Long-term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoiesis Stimulating Agent Treatment
适应症
干预措施
相关药物
试验速览
- 阶段
- 3 期
- 状态
- 已完成
- 入组人数
- 164
- 试验地点
- 25
- 主要终点
- Hemoglobin (Hb) Response Rate from Week 18 to Week 24
研究概览
简要总结
The objective of this study is to evaluate the efficacy and safety of ASP1517 in hemodialysis patients with renal anemia whose treatment is converted from an Erythropoieses Stimulating Agent formulation.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 20 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Subjects with renal anemia who have been receiving ESA (intravenous treatment) within the doses approved in Japan for more than 8 weeks before the screening assessment
- •Mean of the subject's two most recent Hb values during the Screening Period must be ≥10.0 g/dL and ≤12.0 g/dL.
- •Either transferrin saturation (TSAT) ≥ 20% or serum ferritin ≥ 100 ng/mL during the screening period
- •Female subject must either:
- •Be of non-childbearing potential:
- •post-menopausal (defined as at least 1 year without any menses) prior to Screening, or
- •documented surgically sterile Or, if of childbearing potential,
- •Agree not to try to become pregnant during the study and for 28 days after the final study drug administration
- •And have a negative pregnancy test at Screening
- •And, if heterosexually active, agree to consistently use two forms of highly effective birth control (at least one of which must be a barrier method) starting at Screening and throughout the study period and continued for 28 days after the final study drug administration.
- •Female subject must agree not to breastfeed starting at Screening and throughout the study period, and continued for 28 days after the final study drug administration.
- •Female subject must not donate ova starting at Screening and throughout the study period, and continued for 28 days after the final study drug administration.
- •Male subject and their female spouse/partners who are of childbearing potential must be using two forms of highly effective birth control (at least one of which must be a barrier method) starting at Screening and continue throughout the study period, and for 12 weeks after the final study drug administration
- •Male subject must not donate sperm starting at Screening and throughout the study period and, for 12 weeks after the final study drug administration
排除标准
- •Concurrent retinal neovascular lesion requiring treatment and macular edema requiring treatment
- •Concurrent autoimmune disease with inflammation that could impact erythropoiesis
- •History of gastric/intestinal resection considered influential on the absorption of drugs in the gastrointestinal tract (excluding resection of gastric or colon polyps) or concurrent gastro-paresis
- •Uncontrolled hypertension
- •Concurrent congestive heart failure (NYHA Class III or higher)
- •History of hospitalization for treatment of stroke, myocardial infarction, or pulmonary embolism within 12 weeks before the screening assessment
- •Positive for hepatitis B surface antigen (HBsAg) or anti-hepatitis C virus (HCV) antibody at the screening assessment, or positive for human immunodeficiency virus (HIV) in a past test
- •Concurrent other form of anemia than renal anemia
- •Having received treatment with protein anabolic hormone, testosterone enanthate, or mepitiostane within 6 weeks before the screening assessment
- •Aspartate Aminotransferase (AST), Alanine Aminotransferase (ALT), or total bilirubin that is greater than the criteria, or previous or concurrent another serious liver disease at screening assessment
- •Previous or current malignant tumor (no recurrence for at least 5 years is eligible.)
- •Having undergone blood transfusion and/or a surgical procedure consider to promote anemia (excluding shunt reconstruction surgery for access to the blood) within 4 weeks before the screening assessment
- •Having undergone a kidney transplantation
- •Having a previous history of treatment with ASP1517
- •History of serious drug allergy including anaphylactic shock
- •Participation in another clinical study or post-marketing clinical study (including that of a medical device) within 12 weeks before informed consent acquisition
研究组 & 干预措施
ASP1517 Group
Experimental
Study drug will be dosed three times weekly and dose adjustments will be made during the study.
干预措施: roxadustat (Drug)
结局指标
主要结局
Hemoglobin (Hb) Response Rate from Week 18 to Week 24
时间窗: Week 18 to 24
Hb response defined as average Hb within the target range
次要结局
- Average reticulocyte hemoglobin content level(Up to Week 52)
- Average Fe level(Up to Week 52)
- Hb Response Rate from Week 46 to Week 52(Week 46 to 52)
- Average Hb from Week 18 to Week 24(Week 18 to Week 24)
- Average Hb from Week 46 to Week 52(Week 46 to Week 52)
- Change from baseline in the average Hb from Week 18 to Week 24(Baseline and Weeks 18 to 24)
- Change from baseline in the average Hb from Week 46 to Week 52(Baseline and Weeks 46 to 52)
- Proportion of participants with Hb values within the target value in each post-dosing time point(Up to Week 52)
- Change from baseline in Hb to each post-dosing time point(Baseline and Up to Week 52)
- Proportion of measurement points with target Hb level from Week 18 to Week 24(Week 18 to Week 24)
- Proportion of measurement points with target Hb level from Week 46 to Week 52(Week 46 to Week 52)
- Rate of rise in Hb levels (g/dL/week) from week 0 to at the earliest date of week 4, time of discontinuation, or time of dose adjustment(Up to Week 4)
- Average hematocrit level(Up to Week 52)
- Average reticulocyte level(Up to Week 52)
- Quality of life assessed by SF-36(Up to Week 52)
- Number of hospitalizations(Up to Week 52)
- Average ferritin level(Up to Week 52)
- Average transferrin level(Up to Week 52)
- Average total iron binding capacity level(Up to Week 52)
- Average soluble transferrin receptor level(Up to Week 52)
- Average transferrin saturation level(Up to Week 52)
- Quality of life assessed by EQ-5D(Up to Week 52)
- Quality of life assessed by FACT-An(Up to Week 52)
- Safety assessed by standard 12-lead electrocardiogram(Up to Week 52)
- Number of participants with abnormal Laboratory values and/or adverse events related to treatment(Up to Week 52)
- Safety assessed by incidence of adverse events(Up to Week 52)
- Number of participants with abnormal Vital signs and/or adverse events related to treatment(Up to Week 52)
研究者
研究点 (25)
Loading locations...
相似试验
已完成
2 期
A Study to Investigate the Effect of ASP1517 After Intermittent Oral Dosing in Dialysis Chronic Kidney Disease Patients With Anemia Compared With Darbepoetin as a Reference DrugRenal Anemia Associated With Chronic Renal Failure (CRF)NCT01888445Astellas Pharma Inc130
已完成
3 期
A Study of Intermittent Oral Dosing of ASP1517 in Peritoneal Dialysis Chronic Kidney Disease Patients With AnemiaPeritoneal Dialysis Chronic Kidney Disease Patients With AnemiaNCT02780726Astellas Pharma Inc56
已完成
3 期
A Study of Intermittent Oral Dosing of ASP1517 in ESA-untreated Chronic Kidney Disease Patients With AnemiaChronic Kidney DiseaseNCT02964936Astellas Pharma Inc100
已完成
3 期
A Study of Intermittent Oral Dosing of ASP1517 in Erythropoieses Stimulating Agent (ESA)-Naive Hemodialysis Chronic Kidney Disease Patients With AnemiaESA-naive Hemodialysis Chronic Kidney Disease Patients With AnemiaNCT02780141Astellas Pharma Inc75
已完成
3 期
Long-term Study in Chronic Kidney Disease Patients With Hyperphosphatemia Not on DialysisChronic Kidney DiseaseHyperphosphatemiaRenal InsufficiencyNCT01742611Astellas Pharma Inc105